Epidemiological characterization and prognostic factors in patients with confirmed cerebral cryptococcosis in central Taiwan

Journal of Venomous Animals and Toxins Including Tropical Diseases

Volumn 21, Issue 1, 2015, Pages

  Chen, Chang Hua ^a,c   Sy, Hiu Ngar ^a   Lin, Li Jhen ^a   Yen, Hua Cheg ^a   Wang, Shao Hung ^b   Chen, Wei Liang ^a   Chen, Yu Min ^a   Chang, Yu Jun ^a  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^c HUNGKUANG UNIVERSITY   (Taiwan)

Author keywords

Cryptococcus gattii Cryptococcosis; Cryptococcus neoformans; Meningitis; Outcome; Risk Assessment

Indexed keywords

ADULT; AGE; ARTICLE; BLOOD CULTURE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID OPENING PRESSURE; CHRONIC LUNG DISEASE; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HEADACHE; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MORTALITY; PROGNOSTIC ASSESSMENT; TAIWAN; TIME TO TREATMENT;

CRYPTOCOCCUS GATTII; FILOBASIDIELLA NEOFORMANS;

EID: 84934288274     PISSN: 16789180     EISSN: 16789199     Source Type: Journal    
DOI: 10.1186/s40409-015-0012-0     Document Type: Article

References (40)

1. Casadevall A, Perfect JR. Cryptococcus neoformans. Washington, DC: ASM Press; 1998.
2. Vilchez RA, Irish W, Lacomis J, Costello P, Fung J, Kusne S. The clinical epidemiology of pulmonary cryptococcosis in non-AIDS patients at a tertiary care medical center. Medicine (Baltimore). 2001;80(5):308-12.
3. Brizendine KD, Baddley JW, Pappas PG. Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status. PLoS One. 2013;8(3), e60431.
4. Tseng HK, Liu CP, Ho MW, Lu PL, Lo HJ, Lin YH, et al. Taiwan infectious diseases study network for Cryptococcosis. Microbiological, epidemiological, and clinical characteristics and outcomes of patients with cryptococcosis in Taiwan, 1997-2010. PLoS One. 2013;8(4), e61921.
5. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525-30.
6. Chen YY, Lai CH. Nationwide population-based epidemiologic study of cryptococcal meningitis in Taiwan. Neuroepidemiology. 2011;36(2):79-84.
7. Nucci M, Perfect JR. When primary antifungal therapy fails. Clin Infect Dis. 2008;46(9):1426-33.
8. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. 2007;45(1):6-80.
9. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med. 1979;301(3):126-31.
10. Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G, Craven PC, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med. 1987;317(6):334-41.
11. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS associated cryptococcal meningitis. N Engl J Med. 1992;326(2):83-9.
12. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997;337(1):15-21.
13. Lee YC, Wang JT, Sun HY, Chen TC. Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. J Microbiol Immunol Infect. 2011;44(5):338-45.
14. Lai CC, Gau SJ, Hsueh PR. Fungemia caused by non-Candida species. J Microbiol Immunol Infect. 2012;45:262-3.
15. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-third edition. CLSI document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
16. Cote R, Hachinski VC, Shurvell BL, Norris JW, Wolfson C. The Canadian neurological scale: a preliminary study in acute stroke. Stroke. 1986;17:731-7.
17. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2010;50(3):291-322.
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-52.
19. Rutkowski M, Mann W, Derose S, Selevan D, Pascual N, Diesto J, et al. Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente. Am J Kidney Dis. 2009;53(3 Suppl 3):S86-99.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA. 2001;285(19):2486-97.
21. Juarez DT, Sentell T, Tokumaru S, Goo R, Davis JW, Mau MM. Factors associated with poor glycemic control or wide glycemic variability among diabetes patients in Hawaii, 2006-2009. Prev Chronic Dis. 2012;9, e120065.
22. Liao CH, Chi CY, Wang YJ, Tseng SW, Chou CH, Ho CM, et al. Different presentations and outcomes between HIV-infected and HIV-uninfected patients with cryptococcal meningitis. J Microbiol Immunol Infect. 2011;45(2):296-304.
23. Jongwutiwes U, Sungkanuparph S, Kiertiburanakul S. Comparison of clinical features and survival between cryptococcosis in human immunodeficiency virus (HIV)-positive and HIV-negative patients. Jpn J Infect Dis. 2008;61(2):111-5.
24. Chau TT, Mai HN, Phu NH, Nghia HD, Chuong LV, Sinh DX, et al. A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease. BMC Infect Dis. 2010;10:199.
25. Jean SS, Fang CT, Shau WY, Chen YC, Chang SC, Hsueh PR, et al. Cryptococcaemia: clinical features and prognostic factors. QJM. 2002;95(8):511-8.
26. Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4(2), e21.
27. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis. 2010;50(3):338-44.
28. Sun HY, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis. 2009;49(11):1721-8.
29. Bicanic TA, Muzoora C, Brouwer AE, Meintjes G, Longley N, Taseera K, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis. 2009;49(5):702-9.
30. Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008;46(11):1694-701.
31. Antinori S, Galimberti L, Magni C, Casella A, Vago L, Mainini F, et al. Cryptococcus neoformans infection in a cohort of Italian AIDS patients: natural history, early prognostic parameters, and autopsy findings. Eur J Clin Microbiol Infect Dis. 2001;20(10):711-7.
32. Loyse A, Wainwright H, Jarvis JN, Bicanic T, Rebe K, Meintjes G, et al. Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS. 2010;24(3):405-10.
33. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363(9423):1764-7.
34. Bicanic T, Brouwer AE, Meintjes G, Rebe K, Limmathurotsakul D, Chierakul W, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS. 2009;23(6):701-6.
35. Musubire AK, Meya BD, Mayanja-Kizza H, Lukande R, Wiesner LD, Bohjanen P, et al. Challenges in diagnosis and management of Cryptococcal immune reconstitution inflammatory syndrome (IRIS) in resource limited settings. Afr Health Sci. 2012;12(2):226-30.
36. Huits RMHG, Bremmer R, Enting RH, Sprenger HG, van Assen S. Return of meningeal symptoms in a patient treated for cryptococcal meningitis. J Neurol. 2007;254(10):1443-4.
37. van Berkel A, van Lieshout J, Hellegering J, van der Hoeven JG, Pickkers P. Causes of death in intensive care patients with a low APACHE II score. Neth J Med. 2012;70(10):455-9.
38. Knaus WA, Draper AE, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818-29.
39. Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E. IberoAmerican cryptococcal study group: molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis. 2003;9(2):189-95.
40. Kaocharoen S, Ngamskulrungroj P, Firacative C, Trilles L, Piyabongkarn D, Banlunara W, et al. Molecular epidemiology reveals genetic diversity amongst isolates of the Cryptococcus neoformans/C. gattii species complex in Thailand. PLoS Negl Trop Dis. 2013;7(7), e2297.